Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P.
Decaudin D, et al. Among authors: pouillart p.
J Natl Cancer Inst. 2004 Apr 21;96(8):636-7. doi: 10.1093/jnci/djh108.
J Natl Cancer Inst. 2004.
PMID: 15100346
Clinical Trial.
No abstract available.